CLINICAL TRIALS PROFILE FOR FORTOVASE

All Clinical Trials for FORTOVASE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000920 ↗	Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	1969-12-31	The purpose of this study is to see if it is safe to give saquinavir-SGC (SQV) combined with low-dose ritonavir (RTV) plus zidovudine (ZDV) and lamivudine (3TC) to HIV-positive pregnant women and to see if it is safe to give 3TC and ZDV to their newborns. Another purpose is to see what levels of SQV, low-dose RTV, ZDV, and 3TC are found in mothers and what levels of ZDV and 3TC are seen in newborns. Another purpose of this study is to see whether SQV passes from mother to newborn and if it passes at a level that is safe for the newborn. Although ZDV has been able to reduce the rate of transmission of HIV from mother to child, it may be possible to reduce it further by using a combination of anti-HIV drugs. This study adds SQV (a protease inhibitor [PI]) with RTV (another PI) and 3TC (a reverse transcriptase inhibitor) to the mother's ZDV regimen.
NCT00000920 ↗	Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	The purpose of this study is to see if it is safe to give saquinavir-SGC (SQV) combined with low-dose ritonavir (RTV) plus zidovudine (ZDV) and lamivudine (3TC) to HIV-positive pregnant women and to see if it is safe to give 3TC and ZDV to their newborns. Another purpose is to see what levels of SQV, low-dose RTV, ZDV, and 3TC are found in mothers and what levels of ZDV and 3TC are seen in newborns. Another purpose of this study is to see whether SQV passes from mother to newborn and if it passes at a level that is safe for the newborn. Although ZDV has been able to reduce the rate of transmission of HIV from mother to child, it may be possible to reduce it further by using a combination of anti-HIV drugs. This study adds SQV (a protease inhibitor [PI]) with RTV (another PI) and 3TC (a reverse transcriptase inhibitor) to the mother's ZDV regimen.
NCT00002229 ↗	Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients	Completed	Hoffmann-La Roche	Phase 4	1969-12-31	The purpose of this study is to see if it is safe and effective to give saquinavir (as a soft gel capsule taken by mouth) along with 2 other anti-HIV drugs to HIV-infected patients.
NCT00002378 ↗	A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients	Completed	Hoffmann-La Roche	Phase 3	1969-12-31	To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (< 400 copies/ml) at week 24 of study therapy. To determine the absolute change in plasma HIV-1 RNA during the 24 weeks of study treatment. To collect safety data on the treatment regimens. AS PER AMENDMENT 12/12/97: To compare the virologic response of Fortovase (FTV) (Saquinavir) Soft Gel Capsule (SGC) tid plus nucleoside reverse transcriptase inhibitors (NRTIs) versus FTV bid plus NRTIs. Further, to compare the virologic response of FTV tid plus NRTIs versus FTV bid plus Nelfinavir bid plus a NRTI with respect to: the percentage of patients whose plasma HIV-1 RNA level falls below the Amplicor assay level of detection (< 400 copies/ml) at week 24 and week 48.
NCT00002397 ↗	A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease	Completed	Hoffmann-La Roche	Phase 3	1969-12-31	The purpose of this study is to compare the safety and effectiveness of saquinavir SGC plus stavudine (d4T) plus lamivudine (3TC) with that of saquinavir SGC plus nelfinavir plus d4T in patients with HIV-associated kidney disease. This study examines whether these drug combinations are effective in preventing kidney disease from progressing to a stage where it is immediately life threatening. This study also examines the effect these drug combinations have on the level of HIV detected in these patients. Finally, this study evaluates the drug level (the amount of drug found in the body) of these two combinations in patients with kidney disease.
NCT00002447 ↗	A Study to Compare Two Anti-HIV Drug Combinations	Completed	Hoffmann-La Roche	Phase 3	1999-10-01	The purpose of this study is to compare 2 anti-HIV drug combinations.

Clinical Trial Conditions for FORTOVASE

Condition Name

Condition Name for FORTOVASE
Intervention	Trials
HIV Infections	8
AIDS-Associated Nephropathy	1
Directly Observed Therapy	1
Pregnancy	1

Condition MeSH

Condition MeSH for FORTOVASE
Intervention	Trials
HIV Infections	8
Kidney Diseases	1
AIDS-Associated Nephropathy	1

Clinical Trial Locations for FORTOVASE

Trials by Country

Trials by Country for FORTOVASE
Location	Trials
United States	71
Puerto Rico	4
Canada	4
Italy	1
Germany	1

Trials by US State

Trials by US State for FORTOVASE
Location	Trials
New Jersey	6
New York	5
California	5
Illinois	4
Florida	4

Clinical Trial Progress for FORTOVASE

Clinical Trial Phase

Clinical Trial Phase for FORTOVASE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
Phase 1	2

Clinical Trial Status

Clinical Trial Status for FORTOVASE
Clinical Trial Phase	Trials
Completed	7
Terminated	1

Clinical Trial Sponsors for FORTOVASE

Sponsor Name

Sponsor Name for FORTOVASE
Sponsor	Trials
Hoffmann-La Roche	6
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	1
National Institute of Allergy and Infectious Diseases (NIAID)	1

Sponsor Type

Sponsor Type for FORTOVASE
Sponsor	Trials
Industry	7
NIH	2
Other	1

Last updated: May 6, 2026

FORTOVASE (saquinavir) Clinical Trials Update, Market Analysis, and Projections

What is FORTOVASE and where is it positioned commercially?

FORTOVASE is an oral formulation of saquinavir (HIV-1 protease inhibitor). It was developed for HIV therapy and historically targeted adults requiring protease-inhibitor–based regimens. Commercially, FORTOVASE’s market role is constrained by the long timeline since approval, the evolution of HIV treatment (fixed-dose combinations, newer protease inhibitors and integrase-based regimens), and the steady shift toward once-daily and simplified regimens.

Market impact reality check: In the current era of HIV treatment, saquinavir-based regimens are niche compared with modern first-line standards. That shapes both the speed of adoption (limited) and the ceiling for incremental uptake (low), even if trial activity continues.

---

Clinical trials update: what is happening in FORTOVASE’s pipeline?

A current, actionable clinical trials “update” requires verified, up-to-date trial identifiers and status dates (for example, NCT numbers, trial phase, last update posting date, and current recruitment status). Under the information provided in this request, there is no trial dataset (no registry exports, no NCT list, no dates, no sponsor activity) to produce a complete and accurate, evidence-backed update.

Given the requirement to deliver hard data and avoid producing incomplete or speculative trial status, no clinical trials update is provided here.

---

Market analysis: what is the likely addressable market for FORTOVASE today?

FORTOVASE’s addressable market is primarily determined by:

1. Clinician regimen preference for modern HIV therapies
2. Formulary access and payer coverage patterns
3. Drug competition within protease inhibitors and across HIV classes
4. Dosing convenience and treatment simplification trends

High-level segmentation of “likely buyers” (not a claim of current share):

• Patients already stabilized on protease-inhibitor–based therapy where switching is avoided or delayed
• Settings where specific protease inhibitor profiles are used due to historical prescribing patterns or resistance considerations
• Second-line or salvage contexts where alternatives are constrained

Practical market constraint: Even with ongoing use in limited cohorts, HIV therapy has largely migrated toward regimens with:

• higher tolerability,
• once-daily schedules,
• stronger efficacy durability in real-world use,
• better resistance handling, which reduces incremental pull for older multi-step protease inhibitor approaches.

---

Projection model: what does the demand curve likely look like?

Without current evidence on:

• active clinical development,
• new label expansions,
• supply or distribution changes,
• updated utilization data, any quantitative projection would be speculative.

Accordingly, this analysis does not include numeric forecasts.

What can be stated as decision-useful market structure is limited to directional logic:

• Base-case demand for an older saquinavir product is typically stable to declining in developed markets due to regimen evolution.
• Downside is driven by formulary exclusion and replacement by newer agents.
• Upside is only feasible if there is a credible label or guideline trigger tied to new trial outcomes, which is not established in the information provided.

---

Competitive landscape: which product attributes determine whether FORTOVASE can grow?

FORTOVASE’s growth depends on its ability to win on one of these:

• Clinical differentiation (efficacy, resistance barrier, safety in a defined population)
• Operational differentiation (dosing simplicity, fixed-dose availability, improved access)
• Economic differentiation (payer support vs alternatives)

In the absence of evidence of active, label-supporting differentiation, the likely outcome is that adoption remains limited and incremental growth is hard.

---

Commercial and development implications for R&D and investors

For R&D strategists:

• If the objective is to pursue clinical differentiation for saquinavir-based therapy, it must be anchored to modern endpoints and registrational-grade evidence. Without a verified, current trial plan, prioritization decisions cannot be justified with this request’s dataset.

For investors:

• Valuation sensitivity for older HIV assets typically tracks utilization durability and risk-adjusted probability of meaningful label expansion.
• With no documented active trial development in the provided material, the risk profile is dominated by competitive substitution and formulary behavior.

---

Key Takeaways

• FORTOVASE is an oral saquinavir product positioned in HIV protease inhibitor therapy, but contemporary regimen standards reduce incremental market pull.
• A verifiable clinical trials update and numeric market projections cannot be produced from the information provided because no trial registry details or market utilization datasets are included.
• Near-term demand for an older protease inhibitor product is structurally more likely to be stable-to-declining unless a verified label or guideline trigger emerges.

---

FAQs

1) Is FORTOVASE still used in HIV care today?

It has historical use as an HIV protease inhibitor, but current uptake depends on modern regimen standards, formulary placement, and payer coverage.

2) What would most likely drive FORTOVASE growth?

Credible new label differentiation (clinical or safety) supported by verified, registrational trials, or an economic/access advantage strong enough to overcome switching away from older regimens.

3) What is the main market risk for FORTOVASE?

Substitution by newer HIV therapies with simpler dosing and stronger real-world performance, which tends to compress volume growth.

4) How should an investor value older HIV assets like FORTOVASE?

By expected utilization durability plus the probability-weighted value of meaningful label expansion. Without evidence of active development, utilization durability dominates.

5) Can FORTOVASE have upside via new indications?

Upside is possible only if new, verified trial outcomes support an indication that aligns with clinician and guideline demand drivers.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). FORTOVASE (saquinavir) prescribing information. FDA.
[2] ClinicalTrials.gov. (n.d.). Search results for saquinavir / FORTOVASE (by NCT). U.S. National Library of Medicine.